Physician profile
Ajay Kumar
NPI 1376831859
$3,833.96
in general payments reported to CMS, 2019-2025
41 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $344 · 2021: $1,290 · 2023: $389 · 2024: $1,042 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.83 |
| Education | $101.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $571.99 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Tempus Ai, INC | $331.72 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $305.59 | 2020-2025 | Monjuvi, Pemazyre, Zynyz |
| Novartis Pharmaceuticals Corporation | $248.02 | 2020-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $203.60 | 2021 | |
| Glaxosmithkline, LLC. | $190.29 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Biodelivery Sciences International, INC. | $169.19 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $144.53 | 2021-2024 | Ultomiris |
| Genentech USA, INC. | $142.90 | 2021 | |
| Janssen Biotech, INC. | $135.51 | 2021-2025 | Erleada, Rybrevant, Akeega |
| Celgene Corporation | $131.32 | 2021-2023 | Reblozyl |
| Amgen INC. | $114.66 | 2019 | |
| Genzyme Corporation | $113.85 | 2021-2023 | |
| Seagen INC. | $111.86 | 2021-2023 | Padcev |
| Pfizer INC. | $103.18 | 2024-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $92.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.14 | 2023-2024 | Ninlaro, Iclusig |
| Eisai INC. | $67.51 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $63.66 | 2024 | Opdivo |
| Astellas Pharma US INC | $43.41 | 2023-2024 | Xospata |
| Array Biopharma INC | $39.25 | 2023-2024 | Braftovi, Mektovi, Lorbrena |
| Allergan, INC. | $35.47 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $27.44 | 2023 | Alymsys |
| Merck Sharp & Dohme LLC | $27.32 | 2024 | Welireg, Keytruda |
| Puma Biotechnology, INC. | $27.12 | 2025 | |
| Kite Pharma, INC. | $26.86 | 2024 | Yescarta |
| Blueprint Medicines Corporation | $26.50 | 2024 | Ayvakit |
| Immunocore Limited | $24.23 | 2024 | Kimmtrak |
| Bayer Healthcare Pharmaceuticals INC. | $22.90 | 2024 | |
| G1 Therapeutics, INC. | $22.56 | 2023 | Cosela |
| Genmab U.S., INC. | $21.99 | 2024 | Tivdak |
| Mirati Therapeutics, INC. | $21.16 | 2024 | Krazati |
| Tandem Diabetes Care, INC. | $20.58 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ipsen Biopharmaceuticals, INC | $19.57 | 2024 | Onivyde |
| Servier Pharmaceuticals LLC | $19.21 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.96 | 2023 | Gilotrif |
| Boston Scientific Corporation | $17.66 | 2024 | Spaceoar Vue System - 10ml |
| Recordati_rare_diseases_inc. | $17.39 | 2025 | Enjaymo |
| Abbvie INC. | $16.16 | 2023 | |
| Daiichi Sankyo INC. | $13.95 | 2024 | Enhertu |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.